AI-Reviewed Research, Clinical Excellence & Evidence-Based Practice in Aesthetic Medicine— Curated and reviewed by practising aesthetic clinicians
Regulatory updates, product alerts, peer-reviewed research highlights, and HSI announcements — filtered by region. Editorial commentary, not promotional.
Issue 6 leads with a critical evidence review of the therapeutic peptide landscape, alongside articles on necrosis management, dermal filler complications, and migraine prevention with botulinum toxin.
Aesthetic manufacturer Teoxane presented the babyGLOW technique — a standardised, anatomy-based subdermal injection approach using Teosyal Puresense Redensity 1 — at the International Master Course on Ageing Science (IMCAS) in Paris. The method, refined with a board of over 20 expert injectors across six countries, is designed to support consistent product distribution while avoiding facial danger zones. Harley Street Institute notes that anatomy-guided subdermal placement has been integral to its teaching curriculum for several years.
The Harley Street Institute’s open-access journal Aesthetic Intelligence has been formally registered with ISSN 2979-8116, supporting long-term indexing, citation, and archival permanence.
The Medicines and Healthcare products Regulatory Agency has reissued guidance clarifying that BPC-157, TB-500, and similar research peptides remain unlicensed for human use in the UK, with medicinal claims constituting an offence under the Human Medicines Regulations 2012.
The US Food and Drug Administration has updated its consumer and clinician alert on counterfeit Botox vials circulating outside the licit supply chain, following further confirmed adverse events including botulism-like symptoms requiring hospitalisation.
A multi-centre randomised controlled trial published in JAMA Dermatology reports statistically significant improvements in dermal hydration and elasticity at twelve weeks following a three-session polynucleotide protocol versus saline control.
Ireland’s Health Products Regulatory Authority has expanded post-market surveillance requirements for hyaluronic-acid fillers and botulinum toxin products distributed in the Republic, with clinicians encouraged to report adverse events through the online portal.
The Joint Council for Cosmetic Practitioners reports that secondary legislation under Section 180 of the Health and Care Act 2022 is progressing, moving toward statutory licensing for non-surgical cosmetic procedures in England.
A large prospective registry analysis confirms sustained reduction in monthly headache days under the PREEMPT protocol, with response rates broadly mirroring pivotal trial outcomes across diverse populations.
The American Society for Dermatologic Surgery has released a 2026 consensus statement on the recognition and stepwise management of intravascular filler events, reinforcing hyaluronidase dosing and ophthalmology referral thresholds.
The General Medical Council has issued supplementary guidance reinforcing that doctors practising in cosmetic interventions are expected to evidence CPD relevant to their scope of practice — a domain in which structured AiCE-aligned activity contributes.
The Health Information and Quality Authority has opened a consultation that, for the first time, explicitly references non-surgical aesthetic procedures within proposed national standards for private healthcare settings.
The US Food and Drug Administration has declared decisive steps to restrict access to GLP-1 ingredients for non-FDA-approved compounded drugs, and on 30 April 2026 proposed removing semaglutide and tirzepatide from the 503B bulks list, citing stabilising branded supply.
The Medicines and Healthcare products Regulatory Agency has approved a new maximum weekly dose of semaglutide up to 7.2mg for adults with obesity (BMI ≥30 kg/m²). The higher dose is administered as three consecutive 2.4mg injections following a structured escalation schedule, and does not apply to cardiovascular-risk indications.
The US Food and Drug Administration has approved Wegovy as the first once-daily oral GLP-1 weight-loss pill for chronic weight management in adults with obesity. Developed by Novo Nordisk, the tablet contains semaglutide and became available in US pharmacies from January 2026.
Industry news is curated by the HSI editorial board. Items summarise external regulatory, product, and peer-reviewed developments and link to primary sources. They do not constitute clinical guidance. For peer-reviewed analysis, see the main journal.